266 related articles for article (PubMed ID: 37527013)
21. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors.
Wang L; Yang L; Wang C; Zhao W; Ju Z; Zhang W; Shen J; Peng Y; An C; Luu YT; Song S; Yap TA; Ajani JA; Mills GB; Shen X; Peng G
J Clin Invest; 2020 Nov; 130(11):5951-5966. PubMed ID: 33016929
[TBL] [Abstract][Full Text] [Related]
22. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract][Full Text] [Related]
23. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
24. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.
Liu XD; Kong W; Peterson CB; McGrail DJ; Hoang A; Zhang X; Lam T; Pilie PG; Zhu H; Beckermann KE; Haake SM; Isgandrova S; Martinez-Moczygemba M; Sahni N; Tannir NM; Lin SY; Rathmell WK; Jonasch E
Nat Commun; 2020 May; 11(1):2135. PubMed ID: 32358509
[TBL] [Abstract][Full Text] [Related]
25. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
26. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract][Full Text] [Related]
27. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
[TBL] [Abstract][Full Text] [Related]
28. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
29. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
30. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
32. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA
Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647
[TBL] [Abstract][Full Text] [Related]
33.
Terzo EA; Lim AR; Chytil A; Chiang YC; Farmer L; Gessner KH; Walker CL; Jansen VM; Rathmell WK
Oncotarget; 2019 Jan; 10(6):647-659. PubMed ID: 30774762
[TBL] [Abstract][Full Text] [Related]
34. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
[TBL] [Abstract][Full Text] [Related]
35. ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways.
Feng X; Tubbs A; Zhang C; Tang M; Sridharan S; Wang C; Jiang D; Su D; Zhang H; Chen Z; Nie L; Xiong Y; Huang M; Nussenzweig A; Chen J
EMBO J; 2020 Jul; 39(14):e104036. PubMed ID: 32484965
[TBL] [Abstract][Full Text] [Related]
36. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract][Full Text] [Related]
37. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer.
Kabashima A; Matsuo Y; Ito S; Akiyama Y; Ishii T; Shimada S; Masamune A; Tanabe M; Tanaka S
Sci Rep; 2022 Jun; 12(1):10466. PubMed ID: 35773436
[TBL] [Abstract][Full Text] [Related]
38. Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis.
Wu Z; Lin Y; Liu LM; Hou YL; Qin WT; Zhang L; Jiang SH; Yang Q; Bai YR
J Immunol Res; 2022; 2022():7978042. PubMed ID: 35983076
[TBL] [Abstract][Full Text] [Related]
39. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
[TBL] [Abstract][Full Text] [Related]
40. Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
Cui S
Med Sci Monit; 2017 Jul; 23():3360-3366. PubMed ID: 28697172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
